Jw Life Science Corp (234080.KS)
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.
Company Info
Highlights
₩188.76B
₩243.33B
₩61.33B
₩10,000.00 - ₩12,550.00
₩18,000.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Jw Life Science Corp (234080.KS) returned 12.04% year-to-date (YTD) and 5.64% over the past 12 months.
234080.KS
12.04%
5.54%
11.26%
5.64%
-0.02%
-3.60%
N/A
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 234080.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -3.49% | 0.86% | 3.49% | 4.84% | 6.09% | 12.04% | |||||||
| 2024 | -4.58% | 4.64% | -3.27% | 0.16% | -3.05% | -1.16% | -0.25% | -2.52% | -6.12% | 0.09% | 5.14% | -0.69% | -11.57% |
| 2023 | -1.32% | 1.75% | -4.43% | 0.86% | 5.02% | 8.50% | 3.66% | 2.45% | -6.68% | -5.57% | 0.96% | 5.66% | 10.10% |
| 2022 | -6.86% | 15.12% | -1.68% | 3.08% | -8.31% | -9.06% | 9.96% | -7.61% | -11.37% | 3.98% | 5.11% | 2.40% | -8.69% |
| 2021 | 5.30% | -5.26% | -8.21% | 2.63% | -4.87% | 5.12% | -5.90% | -3.27% | -9.30% | 0.62% | -13.89% | 2.88% | -30.83% |
| 2020 | -3.54% | -7.85% | -18.75% | 9.09% | 12.82% | 8.52% | 2.36% | -3.84% | 1.06% | -5.53% | 6.69% | 11.07% | 7.42% |
| 2019 | 2.51% | 8.67% | 0.82% | -1.62% | 6.60% | -10.44% | -2.81% | -1.33% | -4.28% | -5.41% | -9.20% | 11.28% | -7.48% |
| 2018 | 27.32% | -3.17% | 0.96% | 0.00% | -7.25% | 4.94% | -7.06% | 11.60% | -2.46% | -14.73% | 12.50% | -9.15% | 6.82% |
| 2017 | 7.31% | 0.34% | -2.21% | -3.47% | 17.63% | 3.98% | 9.56% | 6.58% | -6.80% | -1.35% | 11.92% | 5.60% | 57.73% |
| 2016 | -19.67% | -27.10% | 11.25% | -34.86% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 234080.KS is 53, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Jw Life Science Corp (234080.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Jw Life Science Corp provided a 4.10% dividend yield over the last twelve months, with an annual payout of ₩500.00 per share. The company has been increasing its dividends for 8 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₩500.00 | ₩500.00 | ₩500.00 | ₩500.00 | ₩500.00 | ₩500.00 | ₩500.00 | ₩500.00 | ₩500.00 | ₩300.00 |
Dividend yield | 4.10% | 4.60% | 3.89% | 4.12% | 3.61% | 2.41% | 2.53% | 2.28% | 2.38% | 2.19% |
Monthly Dividends
The table displays the monthly dividend distributions for Jw Life Science Corp. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩500.00 | ₩500.00 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩500.00 | ₩500.00 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩500.00 | ₩500.00 |
| 2021 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩500.00 | ₩500.00 |
| 2020 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩500.00 | ₩500.00 |
| 2019 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩500.00 | ₩500.00 |
| 2018 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩500.00 | ₩500.00 |
| 2017 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩500.00 | ₩500.00 |
| 2016 | ₩300.00 | ₩300.00 |
Dividend Yield & Payout
Dividend Yield
Jw Life Science Corp has a dividend yield of 4.10%, which is quite average when compared to the overall market.
Payout Ratio
Jw Life Science Corp has a payout ratio of 17.22%, which is below the market average. This means Jw Life Science Corp returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Jw Life Science Corp. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Jw Life Science Corp was 63.91%, occurring on Mar 19, 2020. The portfolio has not yet recovered.
The current Jw Life Science Corp drawdown is 50.58%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -63.91% | Apr 12, 2018 | 475 | Mar 19, 2020 | — | — | — |
| -45.98% | Oct 28, 2016 | 29 | Dec 7, 2016 | 233 | Nov 22, 2017 | 262 |
| -16.44% | Jan 29, 2018 | 8 | Feb 7, 2018 | 36 | Apr 3, 2018 | 44 |
| -12.54% | Nov 24, 2017 | 11 | Dec 8, 2017 | 13 | Jan 2, 2018 | 24 |
| -6.68% | Apr 4, 2018 | 2 | Apr 5, 2018 | 4 | Apr 11, 2018 | 6 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Jw Life Science Corp over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Jw Life Science Corp, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -222.4%.
Valuation
The Valuation section provides an overview of how Jw Life Science Corp is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 234080.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 234080.KS has a P/S ratio of 0.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 234080.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 234080.KS has a P/B value of 0.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |